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Abstract: One of the challenges of cancer is its heterogeneity and rapid capacity to adapt. Notwithstanding 
significant progress in the last decades in genomics and precision medicine, new molecular targets and 
therapies appear highly necessary. One way to approach this complex problem is to consider cancer 
in the context of its cellular and molecular microenvironment, which includes nerves. The peripheral 
nerves, the topic of this review, modulate the biological behavior of the cancer cells and influence tumor 
progression, including the events related to the metastatic spread of the disease. This mechanism involves 
the release of neurotransmitters directly into the microenvironment and the activation of the corresponding 
membrane receptors. While this fact appears to complicate further the molecular landscape of cancer, the 
neurotransmitters are highly investigated molecules, and often are already targeted by well-developed drugs, 
a fact that can help finding new therapies at a fraction of the cost and time needed for new medicines (through 
the so-called drug repurposing). Moreover, the modulation of tumor progression by neurotransmitters can 
probably explain the long-recognized effects of psychological factors on the burden of cancer. We begin 
with an introduction on the tumor-nervous-connections and a description of the perineural invasion and 
neoneurogenesis, the two most important interaction patterns of cancer and nerves. Next, we discuss the 
most recent data that unequivocally demonstrate the necessity of the nervous system for tumor onset and 
growth. We introduce the molecular players of the tumor-nervous-connections by citing the role of three 
main families: neurotropic factors, axon guidance molecules, and neurotransmitters. Finally, we review the 
role the most important neurotransmitters in tumor biology and we conclude by analyzing the significance 
of the presented data for cancer therapy, with all the potential advantages and caveats. 
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Introduction 
Nerves along with blood vessels, immune cells, fibroblasts, and 
the extracellular matrix are part of the tumor microenvironment, 
an established contributor to tumor progression. 
A discussion of the nervous system in the tumor 
environment must at least cite the vascular biology field for 
two reasons. The first is that blood vessels and nerves have 
strong evolutionary relations, display both anatomical and 
molecular similarities, and the fields of vascular biology and 
neurobiology are linked at different levels both in basic and 
translational research. The second is that the formation 
of new blood vessels in tumors, or angiogenesis, is 
considered one of the hallmarks of cancer (1). The so-called 
neurovascular connections have been exhaustively reviewed 
from different angles in the recent years, for example in 
by Quaegebeur and colleagues (2), and will not be treated 
further here. 
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This review is dedicated to the crosstalk between 
tumors and nerves, which we generally call tumor-nervous 
connections (TNCs), and in particular on the role that the 
soluble signals produced by neurons, or neurotransmitters, 
have in cancer. The aim is to attract the interest of both 
basic researchers and clinicians, because neurotransmitters 
have long established functions in the nervous system and 
are potential oncological targets of already used drugs (a 
process called drug repurposing). 
Tumor nervous connections: anatomical aspects
As any two cell systems within an organ, tumor cells and 
nerves make up a complex array of cellular and molecular 
interactions that can be approached from a broad spectrum 
of perspectives, both clinical and experimental. 
For historical reasons the discussion on the TNCs 
starts by citing two main patterns of physical/humoral 
interaction: (I) the invasion of nerves by cancer cells, called 
perineural invasion, and (II) the growth of new axons 
into the tumor tissue, in a way similar to angiogenesis, 
called neoneurogenesis. It should be mentioned that, in a 
reciprocal manner, numerous types of cancers (e.g., breast, 
colorectal, kidney, lung and melanoma) frequently give rise 
to intracranial metastases, infiltrating the central nervous 
tissues (3). This type of TNCs, which obviously represent a 
unique clinical challenge by themselves, will not be treated 
further here. 
Perineural invasion is a process that has been observed 
for centuries and is routinely evaluated by the pathologist 
(4,5), and occurs as peripheral cancers infiltrate the 
surrounding nerve arborescence, wrapping around these 
structures. Virtually all peripheral cancer types have been 
observed to contract interactions with neuronal structures 
at least at advanced stages of the disease, and in particular 
cancer of the bladder (6), prostate (7), pancreas (8), colon (9) 
lung (10), head and neck (11) and bile duct (12). The 
process has been mostly studied for prostate, head and neck, 
and pancreatic carcinomas, and the invasion takes place 
by the destruction of the perineurium and invasion via the 
perforating vessels of the perineurium  (13). 
Neoneurogenesis is the stimulation of axon growth and 
tumor innervation, by producing soluble or cell-to-cell 
signaling components (14). It is well known that peripheral 
nerve cells, in contrast to cells of the central nervous 
system, can regenerate during wound healing (15) and 
the reconstitution of lost body parts in animals. This last 
process and its common ground with nerve outgrowth in 
cancer is of high biological interest and has been reviewed 
recently (16). Because of its nature and similarities to 
angiogenesis, neoneurogenesis has offered the most fertile 
ground for the discovery of molecules and pharmacological 
targets that regulate the TNCs. Nevertheless, PNI and 
neoneurogenesis share, at least at certain stages, cellular and 
molecular events, and will be treated both as TNCs from 
here on, unless differently stated. Along with the axonal 
ingrowth into the tumor as neoneurogenesis, the possibility 
of neogenesis of neuronal cells should be mentioned. 
Indeed, mesenchymal stem cells (MSC), a bone-marrow 
derived population usually recruited by tumor cells, can 
differentiate into neurons under the right conditions (17). 
TNCs: more than casual interactions
Nerves invading cancers were initially thought as “easy 
paths” that allow the spread of tumors cells. This simplified 
version of the facts, as a recurring event in science, has 
now been dismissed. We can now definitely state that 
the nervous system is functionally relevant, modulating 
a complex network of interactions that promote tumor 
progression. Moreover, the interaction between the nervous 
system and the tumors seems to be reciprocal, as cancer 
cells also produce factors that promote nervous system 
development. 
Throughout the rest of this review, we will list a long 
series of relevant descriptive, epidemiological, as well as 
in vitro and in vivo studies that sustain the existence of 
functional TNCs. However, we should begin by describing 
the first proofs, which have been accumulating only in 
the last few years, that the nervous system is, in fact, 
indispensable for tumor onset and growth. These proofs 
consist of the demonstration that ablation of different 
portions of the Peripheral Nervous System prevents 
cancer development in rodent models of prostate (18) 
and gastric (19) cancer, basal cell carcinoma (BCC) (20), 
pancreatic ductal adenocarcinoma (21), melanoma (22), 
and fibrosarcoma (23). The most compelling finding 
across all the reports demonstrated that adrenergic fibers 
from the Sympathetic Nervous System are involved in 
the initial phases of tumor progression, while tumor-
infiltrating cholinergic fibers from the Parasympathetic 
Nervous System are fundamental in tumor cell invasion, 
and migration (18). Sympathetic and parasympathetic 
nerves were found to be necessary throughout all phases of 
prostate cancer development in the mouse. Sympathectomy 
or genetic deletion of β-adrenergic receptors (βAR) 
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prevented the early stages of tumor development, while 
tumors were infiltrated by parasympathetic cholinergic 
fibers that promoted cancer dissemination. Catecholamines 
and acetylcholine (see below) secreted by sympathetic 
and parasympathetic nerves, were responsible for the 
stimulation of prostate tumor growth and metastasis, 
respectively. Notably, catecholamines and acetylcholine, 
secreted by nerves, targeted stromal cells expressing βAR 
and muscarinic receptors. This observation reinforces the 
concept that microenvironment impacts tumor biology. 
Comparable results demonstrated that denervation 
suppresses gastric tumorigenesis (19). In a mouse model 
of gastric cancer, pharmacologic or surgical denervation 
of the stomach, by local injection of neurotoxic agents or 
vagotomy, strongly reduced tumor progression. Importantly, 
denervation also enhanced the therapeutic effect of systemic 
chemotherapy. 
 While a role for sensory nerves could be hypothesized 
from these last results (the vagus nerve contains both 
sensory and autonomic axons), a recent study proved 
this concept (21). In a mouse model of pancreatic ductal 
adenocarcinoma, sensory denervation of the pancreas was 
achieved by specific ablation of sensory neuron by capsaicin. 
In this genetically engineered mouse model, a Kras gain-
of-function mutation and deletion of p53 is targeted to 
the pancreas, resulting in tumors in >95% of mice within 
4 months. Capsaicin-mediated denervation of the pancreas 
was found to correlate with increased survival; mice with the 
greatest sensory neuron loss also had little or no pancreatic 
disease detectable up to 19 months of age. 
 
Tumor nervous connections: an intricate 
network of signaling 
Even though the actual implication of the nervous system 
in cancer progression has begun to be elucidated in the 
past few years by studies such as the above, we are only 
starting to understand the mechanisms of TNCs. A better 
understanding of how the reciprocal systems operate will 
provide new targets for therapeutic intervention against 
cancer progression.
 Which molecules or molecular families mediate the 
TNCs? On a broad perspective, the molecular cues 
involved in TNCs can be separated into three families: (I) 
neurotropic factors e.g., NGF, BDNF, FGF or IGF-II; (II) 
axon guidance molecules, e.g., netrins and their receptors, 
Eph/Ephrin, Plexins/Semaphorins, Slit-Robo and (III) 
neurotransmitters/neuropeptides. The first two families, 
and especially the axon guidance molecules, have been the 
object of enormous interest in the last years, and have been 
exhaustively reviewed (24-28).
Th i s  r ev i ew  w i l l  i n s t e ad  concen t r a t e  on  the 
neurotransmitter family. Neurotransmitters are some of 
the oldest known cellular communicators (29) and are 
“historically” defined as molecules that (I) are present in 
the pre-synaptic neuron; (II) have specific receptors on the 
post-synaptic neuron; (III) are secreted in a Ca2+-dependent 
manner, following pre- synaptic depolarization. Because of 
these specific properties, even though these molecules can 
be produced outside the nervous system, including cancer 
cells themselves, we refer to them as the “neuronal input” 
to tumor progression.
Neurotransmitters are evolutionarily old and secreted 
by a very conserved machinery. In this context, it is worth 
mentioning the widespread expression of neuronal markers 
(especially members of the synaptic machinery, such as 
synaptophysin) in non-neural cancer tissues. This applies 
in particular to small cell lung carcinoma, a particularly 
aggressive form of lung cancer, which shows several features 
of neuronal cells (30) but also to some types of prostate 
and colon cancers (31). Besides representing a fascinating 
biological phenomenon, this could reflect the selection of 
cancer cells presenting a particular phenotype that allows 
them to interact with the nervous system. Moreover, this 
sustains the existence of the so-called neuro-neoplastic 
synapse, which is not an anatomically discrete structure but 
a recently proposed functional entity (14). 
 
Neurotransmitters: the neuronal input to tumor 
progression 
Tumor innervations can release neurotransmitters directly 
into the neuro-neoplastic synapse and interact with cancer 
cells to influence tumor development and progression (32).
The neuroendocrine system, and in particular the 
autonomic nervous system (ANS) branch  as the regulatory 
organ in the body, governs the regulation of tumor cell 
functions and consequently cancer progression. This direct 
influence may also contribute to the molecular explanation 
for the long-standing theory of an effect of psychosocial 
factors on the course of a cancer disease, in addition 
to the downregulation of the immune system by the 
neuroendocrine system (33). 
In the following part, we will describe the role of the 
main members of neurotransmitters family in tumor 
progression, and we will analyze the potential therapeutical 
Arese et al. Neurotransmitters in cancer
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2018;6(5):89atm.amegroups.com
Page 4 of 14
implications whenever it is possible. Table 1 is meant to 
provide a quick reference to the neurotransmitterslisted 
below, with their receptors and examples of targeting drugs. 
The activity of neurotransmitters, as pointed out in the 
very comprehensive review by Mancino and colleagues (24), 
is often subtle and multifaceted. Nevertheless they do 
modulate cancer growth and affect the response to 
chemotherapy. These mediators can be divided into two 
classes: (I) neuropeptides, consisting of bombesin, substance 
P (SP), cholecystokinin (CCK), gastrin, vasoactive intestinal 
peptide (VIP), bradykinin, neurotensin, calcitonin gene-
related peptide (CGRP), adrenomedullin, and the opioid 
peptides such as dynorphin, enkephalin, and endorphin, and 
(II) classic, which consists of epinephrine, norepinephrine, 
dopamine, serotonin, histamine, aspartate, glutamate, glycine, 
gamma-aminobutyric acid (GABA), and acetylcholine.
Neuropeptides 
Neuropeptides are short polypeptides synthesized by 
several cell types that function both as neurotransmitters 
or neuromodulators in the nervous system or peripherally, 
including cancer, as paracrine and endocrine factors to 
regulate diverse physiopathologic processes (63). While 
several neuropeptides have been implicated in tumor 
progression, for space constraints, we will concentrate on 
neuropeptide Y (NPY), and SP, a member of the tachikinins 
family. 
NPY 
NPY is a sympathetic 36 aminoacid neurotransmitter with 
pleiotropic actions that is widely expressed in the CNS, 
peripheral nervous system and other organs. As such it 
modulates many physiological functions ranging from stress 
responses, food intake, reproduction, circadian rhythms, 
anxiety and depression and pain processing (64). It exerts 
its principal activities through neuropeptide receptors 1, 2 
and 5 and in the context of cancer (65), much information 
has been learned from two pediatric diseases with high 
endogenous NPY production—neuroblastoma and Ewing 
sarcoma—that have become models to investigate the role 
of NPY in tumor growth and progression (66). However, 
NPY and its receptor have been found to be expressed in 
cells and vasculatures from a variety of tumors (65) where 
they exert complex effects. It is generally accepted that 
NPY is an angiogenic factor, which strongly induces the 
endothelial cell proliferation, differentiation and migration, 
and promotes vascularization (66). Aside from being T
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synthesized in tumor cells, NPY is also released systemically 
from sympathetic neurons (67). Thus, the growth-
promoting actions of NPY may also be relevant to tumor 
types that only express its receptors. Importantly, systemic 
release of NPY may be triggered by common conditions in 
cancer patients, such as chronic psychological stress or local 
hypoxia (67), and in this context the synergistic interactions 
of NPY with the adrenergic system are particularly 
attractive (68). 
All these findings make NPY a potential target for cancer 
diagnosis and therapy. A variety of potent and specific 
NPY receptor antagonists is available, and many of them 
have been used in animal models and clinical trials. While 
there are no significant reported side effects associated 
with the administration of NPY receptor antagonists in 
animals and people (34), the potential anorexigenic effects 
of NPY receptor blockage in cancer patients would have 
to be carefully monitored. Moreover, the use of a brain-
impenetrable receptor antagonist could prevent such 
adverse central effects, while preserving peripheral activities 
on tumor growth and metastasis (66). 
SP
SP is a peptide of 11 aminoacids that belongs to the 
tachykinin family and is widely expressed in the central, 
peripheral and enteric nervous system of vertebrates. SP 
and its high-affinity receptor (the neurokinin-1 receptor, 
NK1) have been demonstrated to be involved in a many 
physiological and pathophysiological processes such as 
respiration, thermoregulation, cardiovascular control, pain 
transmission, immunomodulation, depression, inflammation 
and oncogenesis (69). Both SP and NK1 are overexpressed in 
several cancers including ovarian, breast, prostate, pancreas 
and thyroid (70). It has been indicated that SP exerts anti-
cancer function through T cells and NK cells-inducing 
immune reactions (71). However, in breast cancer, SP and 
its receptors are implicated in oncogenic transformation, 
and bone marrow metastasis formation (72) The antagonists 
drugs of the NK1 receptor can block the mitogenic effects 
of SP and produce a pro-apoptotic action both in vitro and 
in vivo. Hence neurokinin-1 receptor is a good candidate 
therapeutic target for cancer therapy and neurokinin-1 
receptor antagonists may be useful for cancer treatment (73).
Classic neurotransmitters
Epinephrine and norepinephrine 
Epinephrine and norepinephrine are catecholamines 
derived from the amino acid tyrosine that are secreted 
mainly by the adrenal medulla and the sympathetic nerves, 
respectively. These mediators can directly modulate several 
mechanisms related to tumor progressions, such as cell 
proliferation, survival, and migration. In addition to their 
effect on tumor cells, catecholamines are also known to 
stimulate endothelial cells, immune cells, and fibroblasts 
and therefore have a broad impact on tumor progression 
Most tumor promoting activities of catecholamines 
depend on the activation of the βAR. In ovarian cancer 
cells, epinephrine and norepinephrine can modulate cell 
proliferation, survival, and tumor angiogenesis through 
the activation of the βAR–cyclic AMP–protein kinase A 
pathway (74). βAR activation promotes cell migration 
and metastasis formation in the breast (75), lung (76), 
colon (77) pancreas (78) and facilitates the angiogenic 
switch and the secretion of VEGF and IL-6 by various 
cancer cell lines (79). βAR modulate carcinogenesis 
induced by a tobacco-specific nitrosamine in the lungs of 
hamsters (80).
From the clinical point of view, it is interesting to 
consider the potential role of catecholamines in stress-
induced cancer development. The circulation levels 
of epinephrine and norepinephrine increases during 
psychological stress and depression favoring the initiation 
of cancer (39), while β-blockers have preventive effects in 
the development of cancer in different models, for example 
ovarian cancer and pancreatic ductal adenocarcinoma 
in mice (74,81). Likewise, surgical stress also promotes 
ovarian cancer growth in a mouse model while a β-blocker 
abrogates this effect (82).
Several population-based studies show that patients 
taking adrenergic antagonists for the treatment of 
cardiovascular conditions may have significantly lower 
rates of cancer, including melanoma, lung, breast, prostate, 
and colorectal cancer [reviewed in (40)]. Nevertheless, the 
data are far from conclusive, probably because of many 
confounding factors, such as comorbidities and interaction 
with other drugs (especially aspirin), to name a few. More 
corroborative retrospective studies are needed (83).
Dopamine
Dopamine  i s  a  ca techo lamines  f ami ly  members 
and a precursor of norepinephrine and epinephrine 
synthesis. It is also an important neurotransmitter in the 
brain (84) In peripheral tissues there are at least three 
primary sources of dopamine. These include sympathetic 
neurons, neuroendocrine cells and adrenal medulla (84). 
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Dopamine release causes a “negative feedback” towards 
stress via two types of receptors (D1-like or D2-like receptor 
families) rather than promoting the ‘fight or flight’ response 
of norepinephrine or epinephrine (84). Growing evidence 
suggests that dopamine or dopamine receptor agonists 
act in synergy with anticancer drugs [like doxorubicin or 
5-fluorouracil (5-FU)] (85) and exert an inhibitory effect 
on cancer growth, for example in breast, colon, gastric 
cancers and sarcoma (86-89). Nonetheless, dopamine itself 
does not affect cancer growth. The main anti-cancer effect 
is associated with the inhibitory effect on proliferation 
and migration of tumor endothelial cells by inhibiting the 
phosphorylation of VEGF receptor-2 and preventing the 
activation of mitogen-activated protein kinase (MAPK) 
(86-89). These effects are mainly mediated by dopamine 
receptor 2 which is expressed in the tumor endothelial cells. 
Despite the reported anti-tumor effects of dopamine, there 
is no agreement on the role of the dopaminergic system 
in cancer development, and more epidemiological data is 
needed to reach a consensus. 
Serotonin
Serotonin (5-hydroxytryptamine or 5-HT) is a monoamine 
neurotransmitter, that plays cognitive and behavioral 
functions in humans, with numerous significant peripheral 
roles in the gut, vasculature and immune system (90). 5-HT 
is a potent mitogen for many types of tumor cells such as 
pancreas, lung, bladder, colon and prostate (48,50,91). The 
multifaceted roles of 5-HT are mediated by 5-HT receptors 
(5-HT1–7) widely distributed in the human body. It has been 
shown that 5-HT1A and 5-HT1B receptors are overexpressed 
in prostate cancer tissues, especially in high-grade tumor 
cells (49). Antagonists of 5-HT1A and 5-HT1B inhibit the 
5-HT effect to different extents and induce apoptosis (48-50). 
Therapeutic approaches targeting 5-HT are aimed in two 
directions. The first is to analyze the role of established 
drugs (drug repurposing): three drugs in wide use to treat 
mental disorders (paliperidone, pimozide, and risperidone) 
that are established inhibitors at serotonin receptor 7, are 
under investigation in an adjunctive role in glioblastoma 
treatment (52,92). Furthermore, common therapies for 
stress and anxiety disorders, such as benzodiazepines and 
SSRIs, also inhibit the proliferation and migration of cancer 
cells in vitro (52,93). The second approach is the search 
for new modulators of serotonin signaling. For example, a 
copper-containing respiratory pigment found in a mollusk 
[keyhole limpet hemocyanin (KLH)] that targets the 
serotonergic signaling pathway, inhibits cellular proliferation 
in various human cell cancer lines (94). 
Acetylcholine
Acetylcholine is the neurotransmitter of the parasympathetic 
system, and its biological activity is mediated by nicotinic 
(n-AchR) and muscarinic (m-AchR) acetylcholine receptors 
in the central and peripheral nervous system (95,96). 
AchR are strongly related to cancer because the chemicals 
contained in cigarette smoke bind these receptors. 
Cigarette smoking is known to cause cancers of the lung, 
mouth, pharynx, larynx, esophagus, pancreas, kidney, and 
bladder (97). Nicotine is the most studied component 
in tobacco, and while it is not a carcinogen by itself, it 
promotes proliferation, tumor growth and invasion by 
binding to n-AChRs (98,99). A nicotine derivative, the 
tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) binds to n-AchR with higher 
affinity than their natural ligand acetylcholine (99). In 
recent years, n-AChRs have been identified as important 
regulators of several other cancer types besides lung. In fact, 
activation of n-AChRs induces growth of mesothelioma 
and colon cancer cells (100). Moreover n-AChRs mediate 
angiogenesis through nicotine-induced prostaglandin 
E2 activity, cyclooxigenase-2 (COX-2), and VEGF 
increase (101). 
n-AChRs are also capable of regulating the synthesis and 
release of catecholamines from the adrenal medulla and 
sympathetic nervous endings. Hence, combined cigarette 
smoke exposure with stress stimulation could accelerate 
tumor growth more than smoking or stress alone (102). In 
parallel, nicotine stimulates colon cancer cells proliferation 
through epinephrine production and β-adrenergic 
activation, while β-blockers reverse this effect (103). A 
recent study reports that nicotine and NNK could not 
only elevate the level of norepinephrine and epinephrine 
but also simultaneously decrease the production of 
inhibitory neurotransmitter GABA in the pancreatic 
ductal adenocarcinoma. Conversely, GABA administration 
abolished the tumor promoting effect of nicotine (104). 
These studies demonstrate the importance of the crosstalk 
between neurotransmitters in tumor progression. 
The m-AChRs, the other family of acetylcholine 
receptors, are expressed in most small cell lung carcinomas 
and many non-small cell lung carcinomas (105), while 
a growth-promoting effect of m-AChRs, mediated by 
transactivation of the EGFR/ERK pathway, has been 
demonstrated in colon cancer cells (106). Finally, activation 
of the MAP kinase by m-AChRs induces cell proliferation 
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and protein synthesis in human breast cancer cells (107). 
The potential therapeutic effects of both the n-AchR and 
m-AchR receptor antagonists are under investigation 
(99,108). Interestingly, a muscarinic antagonist currently 
used in the treatment of overactive bladder (e.g., 
darifenacin) can arrest tumor progression including small 
cell lung carcinoma (56). 
Glutamate
Glutamate is the major excitatory neurotransmitter in 
the mammalian central nervous system. Its functions 
are mediated by two classes of receptors: ionotropic and 
metabotropic. The ionotropic glutamate receptors are 
subdivided into three groups: AMPA, NMDA, and Kainate 
receptors. On the other hand, metabotropic (mGlu) 
receptors are G-protein coupled receptors (GPCRs) making 
up a large family divided into many functional subgroups. 
In addition to the well-established role of glutamate in the 
CNS, several reports indicate a function for glutamate and 
its receptors in peripheral tissues (109) and various cancer 
types (110): colorectal (111), glioma (112), gastric (113), 
oral squamous cell carcinoma (114), melanoma  (115). 
The expression of NMDAR could be used for prognostic 
purposes because in oral squamous cell carcinoma the up-
regulation of NMDAR1 is well-correlated with the TN 
stage, tumor size, the presence of lymph node metastases 
and poorer survival (116). 
The other receptor subtype (mGlu) is also involved in 
cancer. In colorectal carcinoma, overexpression of mGluR4 
is associated with poor prognosis (117). In colon cancer cell 
lines, activation of mGluR4 appears to protect cells from 
5-FU toxicity, whereas decreased mGluR4 expression or 
inactivation by antagonists leads to cell death (111). On 
the contrary, in medulloblastoma (118) the expression of 
mGluR4 has been shown to be inversely correlated with 
tumor aggressiveness and recurrence. Thus, the clinical 
significance of glutamate receptor expression may be 
different among the various tumors. 
GABA 
GABA is the main inhibitory neurotransmitter in the 
central nervous system. GABA functions through two 
classes of cellular receptors: (I) the ionotropic GABAA and 
GABAC receptors,  which are ol igomeric chloride 
channels and (II) the metabotropic GABAB receptor. The 
GABAB receptor is a seven-helix receptor and is related to 
the catecholaminergic receptors, which are involved in the 
regulation of tumor cell migration (see above). Different 
reports indicate that GABA or GABAB agonists, reduce 
gastric carcinogenesis in rats (119), inhibit cell migration and 
metastasis formation of colon cancer in mice (62,120), and 
decrease the human hepatocellular carcinoma cell growth 
both in vitro and in vivo (121). In prostate cancer (122), 
however, GABA or GABAB agonist display opposite 
effects. Hence, it seems that a complicated connection 
between GABA/GABA receptors and cancer exist as GABA 
activation can result in different effects in a cancer-type or 
GABA receptor-type dependent manner.
Conclusions and future directions 
We have written this review with two main aims: (I) provide 
the most compelling data proving the role of the nervous 
system in tumor biology and (II) analyze the role of a 
somewhat forgotten class of molecules mediating tumor 
progression, the neurotransmitters. 
Regarding the first point, the last years have brought 
the most important data existing in the field. The fact that 
removal of nerves from the tumor microenvironment is 
sufficient to slow or halt disease progression is particularly 
remarkable because of the strength of the used models 
(mostly genetically modified mouse models), where the 
development of cancer in the absence of intervention is 
almost guaranteed. While these developments are exciting, 
the downside is that their translation into a treatment 
for cancer presents obstacles and conceptual caveats, as 
discussed by Saloman and co-authors (123). First of all 
the manner in which denervation was obtained either 
chemically or surgically in the models is unlikely to be of 
clinical use (124). Only with the ongoing development of 
tools that allow ‘molecular surgery’ on specific populations 
of neurons in the PNS (e.g., neurotoxins that are population 
specific), it may be possible to replicate these data. In any 
case, there is also a staging problem: the most effective 
impact on disease progression occurred early during the 
disease process or even before transformation occurred. 
Thus, at the time of diagnosis, denervation is unlikely to 
benefit the patient by limiting primary tumor growth, 
although, for some cancers, it could slow metastasis (e.g., 
for prostate or pancreatic cancer). One group for which 
denervation could be valuable would be patients who, 
because of family history, are at particular risk of developing 
a type of cancer (e.g., familial chronic pancreatitis). 
Regarding the role of neurotransmitters in cancers, 
which have also been reviewed by Zhi and colleagues (100) 
there are few considerations to make. The first is the role 
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of neurotransmitters as factors released by the nervous 
system in consequence of the psychological pressure that 
the disease produces. Intriguingly, besides acting directly 
on the tumor and its environment, neurotransmitters can 
change the efficiency of the drugs used for the treatment 
of cancer (111). In the future, this parameter (e.g., the 
“level” of neurotransmission) should be taken into account 
while targeting cancer cells with chemotherapy, or even 
with precision drugs that block critical cellular signaling 
pathways. The approach should eventually bring to a 
profiling of the patient, similar to the one used for the 
hormone-responsiveness of certain cancer types. Finally, 
following this line of thought, because of the stress that 
experimental conditions produce, it might be essential 
to reevaluate the method of testing the drugs in animal 
models, as it has been proposed (125). 
The second point is related to the possible role of 
psychoactive drugs in oncology (repurposing). The ongoing 
approaches in this direction have been described for each 
neurotransmitter when feasible. Drug repurposing has 
obvious advantages: the novel and most promising anti-
cancer drugs have prohibitive cost (126), so considering 
established non-cancer drugs for anticancer activity provides 
an opportunity to rapidly advance therapeutic strategies into 
clinical trials, with benefits for the patient and economic 
advantages. On the flip side, although it is evident that 
the neurotransmitter /receptor system has a role in cancer 
biology, it also regulates normal physiological functions in 
the human body. The use of neurotransmitter modulators 
could produce significant side effects with clinical relevance 
in humans. Targeted delivery of drugs at tumor sites 
represents a very appealing direction in cancer therapy, but 
it obviously needs much more development (127). In our 
opinion it is likely that an advantageous exploitation of the 
TNCs in cancer therapy will come from a combination of 
biotechnological improvements, drug development, patient 
stratification and careful clinical evaluation of the risk to 
benefits ratio. 
Finally, we should consider the (many) open questions 
that remain in this field, and the steps that our laboratory 
is taking to contribute data to the field. Starting again 
from the excellent synthesis made by Saloman and co-
authors (123), the outstanding questions are: (I) is there a 
difference in the impact of different branches of the PNS 
for the development of various tumor types? For example, 
the microenvironment of colorectal cancer, the third 
most common cancer in both men and women (American 
Cancer Society, Cancer Facts and figures, 2017. Atlanta, 
American Cancer Society; 2017), is highly innervated by the 
autonomic fibers, and the presence PNI is associated with 
shortened patient survival in colon cancer (128). However, 
a direct proof impact of nerves on colorectal cancer 
progression has not been reported; (II) is inflammation, 
with its links to neurotransmission, only protumorigenic 
or does it contribute to anticancer conditions? (III) Does 
deregulated nerve–nerve communication contributes to 
cancer pathology? (IV) Do and how other cell types (e.g., 
endothelial, fibroblast or immune) modulate nerve–tumor 
interactions? (V) Are there molecules in nerve–tumor 
signaling that can be used as biomarkers? Can we improve 
prognosis by modulating the signaling of molecules 
identified as participants in nerve-tumor signaling? 
The ongoing projects in our laboratory are aimed at 
answering the last question. We have focused for about 
a decade on the role in blood vessels of a new family of 
neuronal proteins, Neurexins and Neuroligins, which are 
transmembrane synaptic proteins that modulate pre-post 
synaptic communication. We have found that these proteins 
are expressed throughout the vascular system and modulate 
diverse functions, including vessel tone and morphogenesis, 
by affecting various forms of cell-to-cell communication 
(129-137). Thanks to the accumulated experience and 
reagents, more recently we concentrated on the role of 
Neuroligins in tumor progression, and we have found that 
these proteins are indeed expressed by cancers cells of 
different origin (unpublished data). Hence, in the context 
of TNCs and more in general in tumor-stroma relations, 
Neuroligins are uniquely expressed by cancer cells, nerves 
and endothelial cells. Our actual working hypotheses, 
that tackle the possible role of Neuroligin isoforms in 
neurotransmitter activity in the tumor microenvironment, 
are the following. The first is that one isoform of Neuroligin 
(NLGN2) that is involved in insulin granules exocytosis 
from pancreatic beta cells (138) and in the secretion of 
granules called Weibel Palade Bodies from endothelial cells 
(our own unpublished data), also controls the release of 
catecholamines from sympathetic nerves. This is because 
the β cell insulin secretory apparatus is remarkably similar 
to the presynaptic secretory machinery (139). A positive 
answer to this question would make NLGN2 a key protein 
for the modulation of catecholamines activity in cancer. 
The second working hypothesis is that another isoform 
of Neuroligin (NLGN1), that modulates the exposure of 
NMDAR on the surface of neurons (140), also modulates 
the exposure of the receptor on cancer cells, thus affecting 
their response to glutamate. 
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In conclusion, we realize that this review has posed 
many questions along with the presented data, and that the 
role of neurotransmitters in cancer is particularly complex 
and multifaceted. However, we think that if the crucial 
necessity of the nervous system for tumor growth is taken 
into account, this will attract the interest of scientist from 
multiple disciplines, thus opening new prospects for cancer 
treatment. 
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